Recent

% | $
Quotes you view appear here for quick access.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

jetmanbash 132 posts  |  Last Activity: May 26, 2016 7:05 AM Member since: Dec 29, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • jetmanbash jetmanbash May 26, 2016 7:05 AM Flag

    Many more problems for VICL lay ahead. t

  • Reply to

    AEGR death spiral

    by soriya999 May 16, 2016 4:25 PM
    jetmanbash jetmanbash May 26, 2016 6:56 AM Flag

    5th generation lawsuit just announced, or least will probably be announced as another legal firm announced that they are looking into AEGR now. Even if they can make payments on the $40 million FDA penalty with so many lawsuits going on in really five categories/generations those legal expense will suck out most of the remaining cash. I also see civil suits going against Mr. Beer as a distinct possibility and the company could get sucked into more legal expenses representing themselves in those as well. t

  • Could be even more than that, but probably that will be the number. Even with that the stock will still sell for less than five bucks making it non-margin able and not really able to be bought by mutual funds. Continued decay in the vicl franchise. t

  • Reply to

    patent ?

    by smegggy May 22, 2016 9:08 AM
    jetmanbash jetmanbash May 26, 2016 6:25 AM Flag

    IONS has their own version of CRISPR. It has a two protein configuration, is 75 times more potent than the CRISPR Cas9, and they should be able to avoid the complex patent malaise that presently sits over companies like EDIT. t

  • jetmanbash jetmanbash May 24, 2016 10:09 PM Flag

    Only when you look in the mirror and ask yourself. t

  • jetmanbash jetmanbash May 24, 2016 10:08 PM Flag

    ARIA, VRTX, REGN all over twenty some years old. No one has as dominant position in their space as IONS does. That is why the number one cancer center in the US, MDA, has gone with them. Maybe the Republic of Hornsefield will choose vicl. t

  • Reply to

    greatest short in the world

    by kenwcundiff May 24, 2016 12:10 PM
    jetmanbash jetmanbash May 24, 2016 10:05 PM Flag

    Look to buy vicl for a dime soon. Down pretty big in after hours. t

  • jetmanbash jetmanbash May 23, 2016 9:33 PM Flag

    Main question is, Is vicl over 40 cents a share? And when will it be over a dollar? And how long before they get taken over to the pink sheets. t

  • jetmanbash by jetmanbash May 23, 2016 9:18 PM Flag

    One has to hope that this drug works for those SMA kids. But one also has to look at what GS may be doing. They have pumped the max out of this stock.....probably getting ready for the announcement of secondary offering. Also, AVXS has clamped down on FB info on treated patients. There are several reasons that this could be: Competitive reasons, possible HIPPA violations, possible side-effects that have to be studied further, and worries about upsetting the FDA. Price point at this time really doesn't fully reflect the risk, wall street is giving it a coronation for the drug of choice for SMA Type 1. t

  • Exelixis announces 'positive' topline results from Cabosun phase 2 trial of cabozantinib in patients with previously untreated advanced renal cell carcinoma, trial met primary endpoint (5.56)
    The trial met its primary endpoint, demonstrating a 'statistically significant' and 'clinically meaningful' improvement in progression-free survival for cabozantinib compared with sunitinib in patients with advanced intermediate- or poor-risk RCC
    The safety data in the cabozantinib-treated arm of the study were consistent with those observed in previous studies in patients with advanced RCC. Cabosun is being conducted by The Alliance for Clinical Trials in Oncology as part of Exelixis' collaboration with the National Cancer Institute's Cancer Therapy Evaluation Program
    Exelixis will share the results of Cabosun with regulatory authorities to discuss potential next steps in the development and submission strategy for cabozantinib as a treatment of first-line advanced renal cell carcinoma. Exelixis is also working closely with clinical advisors on the development plan for cabozantinib in future clinical trials in other genitourinary malignancies
    The final results from Cabosun will be submitted for presentation at a future medical conference

  • Reply to

    Fools and Jewels and IONS

    by mk4872987 May 20, 2016 2:47 PM
    jetmanbash jetmanbash May 21, 2016 10:09 PM Flag

    I think you are right MK. Their ApoC III inhibitor has a chance to really change the lipid world in regards to risk. Latest research shows that statins don't really work very well in women. In fact, women who are diagnosed with CV disease later in life with DM Type 2 don't receive any benefit at all from their use. Moreover, they have have a much higher risk of CV disease from elevated triglycerides compared to men. This drug could thus be the drug that treats the major modulator of risk and lipids in that population of women. The PCSK9 inhibitor drugs have been very slow to get out of the gate. They are now touting and studying their effects on Lp(a) to help bring in more demand for their drugs. However, they won't be able to come close to lowering Lp(a) like IONS drug can. They thus are helping IONS cause by bringing awareness to this situation and if they have large studies that prove that in fact Lp(a) is truly a risk factor in certain populations that really opens up the door for IONS drug to be a huge success. As far as CRISPR is concerned, IONS has developed their own version of CRISPR. The advantages it has is that it is a two protein entity vs. the three protein ones that are out there now. Moreover it is 75 times more potent than what is out there right now. They also will probably have sole possession of this and not have to fit with all of the people that have patents for CRISPR now. For example, EDIT is a CRISPR biotech. I wouldn't however count on them having sole possession of the technology that they are using and I would anticipate some court battles with others on this in this regard. We will see very soon the full extension of IONS work over the past two decades. Just one huge success like their work with BIIB for Alzheimer Disease, or Parkinson Disease will put them up with a REGN....which BTW took over twenty years to really see success too. t

  • When someone writes a good informative piece on the potential of RNN they get an automatical get a thumbs down from President Putin, why----------because, because of ego t

  • Reply to

    ASCO Abstracts Out

    by peanut.hull May 18, 2016 7:07 PM
    jetmanbash jetmanbash May 18, 2016 7:58 PM Flag

    Got a meeting tonight Peanut but will post the results from I think NVCR on pancreatic CA. That drug is our competitive gold standard. I'd like to see our latest info too. t

  • Reply to

    AEGR death spiral

    by soriya999 May 16, 2016 4:25 PM
    jetmanbash jetmanbash May 17, 2016 8:54 PM Flag

    Agree, the new CEO is really a person that could have helped this company. But Mr. Beer left it in shambles. I've never seen anything like this before. There are going to be four generations of lawsuits against this company. There are the first generation lawsuits where Mr. Beer first disappointed on earnings, then the lawsuits where Mr. Beer got the company in trouble with the FDA, then the third generation of lawsuits where the company really disappointed on earnings, and finally this fourth generation of lawsuits in the ruins of the Beer "ruling" era with another big miss that has nithing to do with the new CEO.. t

  • Stocks that traded to 52 week lows: AAL, AAPL, ABC, ACST, ADRO, AEGR, ALJ, ALNY, AMAG, AMRI, APRI, ARDX, ARKR, ARP, ASX, ATRC, BBEP, BKE, BLUE, BPMX, CAL, CALA, CCCL, CCM, CFRX, CGNT, CHMA, CIDM, CLNT, CLRB, CLVS, CNCE, CONN, CORI, DDS, DHX, DRNA, EGLT, ENDP, EPRS, ERIC, ERJ, ETAK, ETRM, FRGI, FRSH, FSNN, FUR, GBSN, GES, GIII, GILD, GPRO, GPS, HAE, HHS, HRB, HSGX, ICLR, IFON, IMGN, IMMR, IMNP, INFI, INSY, IONS, IVTY, JBL, JGW, JWN, KMPH, KSS, KTWO, KZ, LB, LC, LIFE, LINE, LNCO, M, MATX, MDXG, MSON, NEON, NEOS, NLNK, NOK, NVCN, NVFY, NWBO, OCN, ODP, ONDK, ONP, PARR, PERI, PMTS, PRGO, PTSI, PTX, QKLS, REED, RENN, RGLS, RKDA, SEAC, SHLD, SNFCA, SOHU, SQNM, STAA, STX, TAX, TBI, THRM, TLYS, TRK, VG, VIRT, VNET, VRX, WAC, WDC, WOWO, XCOM, XENT, XNY, XOMA, ZBRA

    See how many are biotechs on this list. t

  • jetmanbash jetmanbash May 12, 2016 1:31 AM Flag

    The market is giving the whole success story to AVXS. It was the FAST group for SMA with their exposure that pressured the FDA to look at and change the primary endpoints for IONS SMArx drug. A huge undervalue and misunderstanding in regards to wall street. t

  • jetmanbash by jetmanbash May 10, 2016 8:15 PM Flag

    Just to make people aware of AVEO's drug for RCC. This isn't really going to be easy to compare to because this study will employ a checkpoint inhibitor along with their drug. It will be interesting to see if RNN will be able to get into a study using a checkpoint inhibitor as well


    AVEO Oncology reports Q1 EPS of ($0.13) vs ($0.13) single estimate; continues to work toward the potential initiation of patient enrollment in the TIVO-3 Study in Q2 (0.90 -0.01)
    AVEO ended Q1 2016 with $23.8 million in cash, cash equivalents and marketable securities. The reduction in cash over base operations was primarily attributable to clinical trial startup costs related to the TIVO-3 study and a significant pay down in accounts payable quarter over quarter. AVEO believe that its cash resources would allow the Company to fund its current operations into the fourth quarter of 2017. This estimate does not include the payment of potential licensing milestones to third parties or the uncommitted costs of conducting any contemplated clinical trials (such as a second phase 3 trial and PD-1 combination trial for tivozanib in RCC), and assumes no milestone payments from our partners, no additional funding from new partnership agreements, no equity financings, no debt financings, no accelerated repayment thereof and no further sales of equity under our ATM. t

  • jetmanbash by jetmanbash May 9, 2016 10:06 PM Flag

    There can be this criticism that these drugs and this company is risky.....and it is and they are. But as time goes on and there is continued good news as far as meeting expectations wall street will have to recognize that there is something here and the approach with hitting cells only containing CA biomarkers may approach the NK, and CART-1 technologies if efficacy in treating CA at a fraction of the cost. t

  • jetmanbash jetmanbash May 9, 2016 9:22 PM Flag

    Peanut, I agree with your assessment. The drug from EXEL has many more side-effects and so far doesn't seem to be as effective. But as you note the Archexin study size is very small. The EXEL drug prior to approval had 658 patients enrolled. Thus Archexin if approved may be will have to fall to third line therapy. The EXEL drug is now considered the first drug for second line therapy. As we know, up to this point survival is only 15% with Stage IV RCC. The EXEL drug data is considered robust by oncology standards. Here is the other facts and targets for Archexin. The drug from EXEL prolonged life for 21.4 months compared to placebo, and the competing drug in the study prolonged life by 16.5 months. Thus the EXEL drug had a 7.4 month vs. a 3.8 month prolonged survival length of time. Thus those are the most important numbers for us to remember. Overall survival is the most important variable followed by progression free survival and then objective recurrence rate. The biggest competitor besides EXEL will be/is from NVS so we need to watch their data too. I believe that this drug from RNN can actually be better in both efficacy and with less side-effects compared to the EXEL drug for the indication of RCC. One has to remember that just like RNN has several drugs going for several indications, this EXEL drug is going for several indications including liver cancer and non-small cell lung CA. t

  • Reply to

    Plenty of reasons for ions to be $10 today !

    by nycknowsbest May 6, 2016 2:09 PM
    jetmanbash jetmanbash May 9, 2016 9:01 PM Flag

    Look for an earlier than expected approval for IONS SMA drug. t

AEGR
1.82+0.09(+5.20%)May 27 4:00 PMEDT